Investor Relations

NYSE: NVRO

Price

95.43 +1.34 ( +1.42% ) 12:50 3/29/17 Pricing delayed 20 minutes

Volume 137,791

Recent News

See All
February 23, 2017 Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months and full year ended December 31, 2016 . 2016 Accomplishment & Highlights: Achieved revenue of $228.5 million for the full year 2016, an increase of 228% as reported, over the prior year U.S. revenue of $173.3 million for 2016, an increase of 612% over the prior year International revenue of $55.2 million for 2016, an increase of 26% in constant currency and 22% on an as-reported basis, both over the prior year Achieved revenue of $70.5 million in the fourth quarter of 2016, an increase of 113% as reported, over the same period of the prior year U.S. revenue of $56.0 million for the fourth quarter of 2016, an increase of 183% over the same period of the prior year International revenue of $14.5 million in the fourth quarter of 2016, an increase of 12% in constant currency and 9% on an...
February 9, 2017 Nevro to Report Operating Results for the Fourth Quarter and Full Year 2016
Nevro to Host Conference Call on Thursday, February 23, 2017 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the fourth quarter and full year of 2016 after market close on Thursday, February 23, 2017 . Company management will host a conference call beginning at 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on Thursday, February 23, 2017 . Investors interested in listening to the conference call may do so by dialing (877) 201-0168 for U.S. callers, or (647) 788-4901 for international callers (Conference ID: 65198382), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California , Nevro...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza System is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.